New cell therapy targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase trial tests a new treatment called CLDN6 CAR-T, which uses a patient's own immune cells to fight solid tumors that have returned or not responded to standard therapy. The treatment targets a protein called CLDN6 found on tumor cells. The study will enroll about 2…
Phase: PHASE1 • Sponsor: BioNTech Cell & Gene Therapies GmbH • Aim: Disease control
Last updated May 17, 2026 04:35 UTC